{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:59:32Z","timestamp":1792839572959,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinisch-Wissenschaftlichen Fonds des B\u00fcrgermeisters der Bundeshauptstadt Wien","award":["18062"],"award-info":[{"award-number":["18062"]}]},{"name":"\u00c4rztekammer f\u00fcr Wien","award":["0023-WS2020"],"award-info":[{"award-number":["0023-WS2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Porto-sinusoidal vascular disorder (PSVD) is a recently defined vascular liver disease. Since diagnosis remains challenging, we aimed to evaluate radiological features that are distinct between PSVD and cirrhosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical, laboratory, and radiological parameters (CT\/MRI) of patients with histologically-confirmed PSVD vs. cirrhosis vs. non-cirrhotic parenchymal liver disease were retrospectively evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-three PSVD, 155 cirrhosis, and 41 non-cirrhotic patients were included. As compared to cirrhosis, PSVD patients were younger and had lower HVPG, liver stiffness, and MELD. Routine clinical and imaging findings indicative of portal hypertension were similarly common. Intrahepatic portal tract abnormalities (49% vs. 15%; <jats:italic>p<\/jats:italic> &lt; 0.001), FNH-like lesions (30% vs. 1%; <jats:italic>p<\/jats:italic> &lt; 0.001), and abnormal liver morphology defined as peripheral parenchymal atrophy and compensatory hypertrophy of central segments (32% vs. 7%; <jats:italic>p<\/jats:italic> &lt; 0.001) were significantly more common in PSVD patients. Hypertrophy of segment I (70% vs. 84%; <jats:italic>p<\/jats:italic> = 0.019), atrophy of segment IV (24% vs. 47%; <jats:italic>p<\/jats:italic> = 0.001), and nodular liver surface (22% vs. 89%; <jats:italic>p<\/jats:italic> &lt; 0.001) were more common in patients with cirrhosis. In patients with gadoxetic acid\u2013enhanced MRI, we identified the distinct imaging feature of \u201cperiportal hyperintensity\u201d in the hepatobiliary phase (HBP) in 42% of patients with PSVD (14\/33) vs. 1% in cirrhosis (1\/95) vs. 0% in non-cirrhotic controls (0\/41); <jats:italic>p<\/jats:italic> &lt; 0.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Diagnosis of PSVD must be considered in younger patients presenting with clinical features of portal hypertension, portal tract abnormalities, and FNH-like lesions on CT\/MRI. \u2018Periportal hyperintensity\u2019 in the HBP of gadoxetic acid\u2013enhanced MRI was identified as a specific radiological feature of PSVD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:italic>\u2022 Cross-sectional imaging can provide essential information to identify patients with porto-sinusoidal vascular disorder (PSVD).<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 Intrahepatic portal tract abnormalities, FNH-like lesions, and abnormal liver morphology are common in PSVD patients.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 Periportal hyperintensity on the hepatobiliary phase of gadoxetic acid\u2013enhanced MRI seems to be specific for patients with PSVD.<\/jats:italic><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00330-022-09132-4","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T10:02:51Z","timestamp":1664272971000},"page":"1422-1432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder"],"prefix":"10.1007","volume":"33","author":[{"given":"Katharina","family":"Lampichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"W\u00f6ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Simbrunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Jachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Josef Maria","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Burghart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Tamandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ba-Ssalamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Scharitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"9132_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","volume":"4","author":"A De Gottardi","year":"2019","unstructured":"De Gottardi A, Rautou PE, Schouten J et al (2019) Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol 4:399\u2013411","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"9132_CR2","doi-asserted-by":"publisher","unstructured":"W\u00f6ran K, Semmler G, Jachs M et al (2020) Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2020.11.039","DOI":"10.1016\/j.cgh.2020.11.039"},{"key":"9132_CR3","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.3748\/wjg.v26.i22.3000","volume":"26","author":"O Nicoar\u0103-Farc\u0103u","year":"2020","unstructured":"Nicoar\u0103-Farc\u0103u O, Rusu I, Stef\u0103nescu H, Tan\u021b\u0103u M, Badea RI, Procope\u021b B (2020) Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease. World J Gastroenterol 26:3000\u20133011","journal-title":"World J Gastroenterol"},{"key":"9132_CR4","doi-asserted-by":"publisher","unstructured":"Elkrief L, Lazareth M, Chevret S et al (2020) Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Hepatology. https:\/\/doi.org\/10.1002\/hep.31688","DOI":"10.1002\/hep.31688"},{"key":"9132_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.dld.2012.05.005","volume":"44","author":"S Seijo","year":"2012","unstructured":"Seijo S, Reverter E, Miquel R et al (2012) Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis 44:855\u2013860","journal-title":"Dig Liver Dis"},{"key":"9132_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jceh.2017.03.002","volume":"7","author":"P Sharma","year":"2017","unstructured":"Sharma P, Agarwal R, Dhawan S et al (2017) Transient elastography (fibroscan) in patients with non-cirrhotic portal fibrosis. J Clin Exp Hepatol 7:230\u2013234","journal-title":"J Clin Exp Hepatol"},{"key":"9132_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/liv.14758","volume":"41","author":"R Paternostro","year":"2021","unstructured":"Paternostro R, Bardach C, Hofer BS et al (2021) Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. Liver Int 41:799\u2013809","journal-title":"Liver Int"},{"key":"9132_CR8","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1111\/liv.14648","volume":"40","author":"L Beer","year":"2020","unstructured":"Beer L, Bastati N, Ba-Ssalamah A et al (2020) MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. Liver Int 40:2797\u20132807","journal-title":"Liver Int"},{"key":"9132_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1148\/radiol.2019190734","volume":"294","author":"N Bastati","year":"2020","unstructured":"Bastati N, Beer L, Mandorfer M et al (2020) Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease? Radiology 294:98\u2013107","journal-title":"Radiology"},{"key":"9132_CR10","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1007\/s00261-020-02779-x","volume":"45","author":"S Poetter-Lang","year":"2020","unstructured":"Poetter-Lang S, Bastati N, Messner A et al (2020) Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 45:3532\u20133544","journal-title":"Abdom Radiol (NY)"},{"key":"9132_CR11","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1007\/s00330-019-06182-z","volume":"29","author":"L Beer","year":"2019","unstructured":"Beer L, Mandorfer M, Bastati N et al (2019) Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol 29:6600\u20136610","journal-title":"Eur Radiol"},{"key":"9132_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1148\/radiol.12111785","volume":"263","author":"A-S Glatard","year":"2012","unstructured":"Glatard A-S, Hillaire S, d\u2019Assignies G et al (2012) Obliterative portal venopathy: findings at CT imaging. Radiology 263:741\u2013750","journal-title":"Radiology"},{"key":"9132_CR13","doi-asserted-by":"publisher","first-page":"20140653","DOI":"10.1259\/bjr.20140653","volume":"88","author":"A Arora","year":"2015","unstructured":"Arora A, Sarin SK (2015) Multimodality imaging of obliterative portal venopathy: what every radiologist should know. Br J Radiol 88:20140653","journal-title":"Br J Radiol"},{"key":"9132_CR14","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00261-018-1570-8","volume":"43","author":"S Rajesh","year":"2018","unstructured":"Rajesh S, Mukund A, Sureka B, Bansal K, Ronot M, Arora A (2018) Non-cirrhotic portal hypertension: an imaging review. Abdom Radiol (NY) 43:1991\u20132010","journal-title":"Abdom Radiol (NY)"},{"key":"9132_CR15","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00261-020-02831-w","volume":"46","author":"JH Kang","year":"2021","unstructured":"Kang JH, Kim DH, Kim SY et al (2021) Porto-sinusoidal vascular disease with portal hypertension versus liver cirrhosis: differences in imaging features on CT and hepatobiliary contrast-enhanced MRI. Abdom Radiol (NY) 46:1891\u20131903","journal-title":"Abdom Radiol (NY)"},{"key":"9132_CR16","doi-asserted-by":"publisher","unstructured":"Valainathan SR, Sartoris R, Elkrief L et al (2022) Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: a case-control study. Hepatology. https:\/\/doi.org\/10.1002\/hep.32367","DOI":"10.1002\/hep.32367"},{"key":"9132_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s12072-020-10112-3","volume":"14","author":"B Simbrunner","year":"2020","unstructured":"Simbrunner B, Semmler G, Stadlmann A et al (2020) Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatol Int 14:1093\u20131103","journal-title":"Hepatol Int"},{"key":"9132_CR18","doi-asserted-by":"publisher","unstructured":"Jachs M, Hartl L, Simbrunner B et al (2021) Decreasing von Willebrand factor levels upon nonselective beta blocker therapy indicate a decreased risk of further decompensation, acute-on-chronic liver failure, and death. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2021.07.012","DOI":"10.1016\/j.cgh.2021.07.012"},{"key":"9132_CR19","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1007\/s00261-018-1502-7","volume":"43","author":"V Vilgrain","year":"2018","unstructured":"Vilgrain V, Paradis V, Van Wettere M, Valla D, Ronot M, Rautou PE (2018) Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdom Radiol (NY) 43:1968\u20131977","journal-title":"Abdom Radiol (NY)"},{"key":"9132_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1148\/radiol.2243011495","volume":"224","author":"H Awaya","year":"2002","unstructured":"Awaya H, Mitchell DG, Kamishima T, Holland G, Ito K, Matsumoto T (2002) Cirrhosis: modified caudate-right lobe ratio. Radiology 224:769\u2013774","journal-title":"Radiology"},{"key":"9132_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s11604-020-00978-6","volume":"38","author":"K Ozaki","year":"2020","unstructured":"Ozaki K, Kozaka K, Kosaka Y, Kimura H, Gabata T (2020) Morphometric changes and imaging findings of diffuse liver disease in relation to intrahepatic hemodynamics. Jpn J Radiol 38:833\u2013852","journal-title":"Jpn J Radiol"},{"key":"9132_CR22","doi-asserted-by":"crossref","unstructured":"EASL (2016) Clinical Practice Guidelines Vascular diseases of the liver.\u00a0J Hepatol 64:179\u2013202","DOI":"10.1016\/j.jhep.2015.07.040"},{"key":"9132_CR23","doi-asserted-by":"publisher","first-page":"20190989","DOI":"10.1259\/bjr.20190989","volume":"93","author":"CL Hui","year":"2020","unstructured":"Hui CL, Mautone M (2020) Patterns of enhancement in the hepatobiliary phase of gadoxetic acid-enhanced MRI. Br J Radiol 93:20190989","journal-title":"Br J Radiol"},{"key":"9132_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11604-012-0136-x","volume":"31","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Matsui O, Gabata T et al (2013) Intrahepatic periportal high intensity on hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI: imaging findings and prevalence in various hepatobiliary diseases. Jpn J Radiol 31:9\u201315","journal-title":"Jpn J Radiol"},{"key":"9132_CR25","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00261-018-1482-7","volume":"43","author":"E Unal","year":"2018","unstructured":"Unal E, Karaosmanoglu AD, Ozmen MN, Akata D, Karcaaltincaba M (2018) Hepatobiliary phase liver MR imaging findings after Oxaliplatin-based chemotherapy in cancer patients. Abdom Radiol (NY) 43:2321\u20132328","journal-title":"Abdom Radiol (NY)"},{"key":"9132_CR26","doi-asserted-by":"publisher","first-page":"e14784","DOI":"10.1097\/MD.0000000000014784","volume":"98","author":"H Onishi","year":"2019","unstructured":"Onishi H, Theisen D, Zachoval R, Reiser MF, Zech CJ (2019) Intrahepatic diffuse periportal enhancement patterns on hepatobiliary phase gadoxetate disodium-enhanced liver MR images: do they correspond to periportal hyperintense patterns on T2-weighted images? Medicine (Baltimore) 98:e14784","journal-title":"Medicine (Baltimore)"},{"key":"9132_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2214\/AJR.11.6855","volume":"198","author":"P Krishnan","year":"2012","unstructured":"Krishnan P, Fiel MI, Rosenkrantz AB et al (2012) Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol 198:370\u2013376","journal-title":"AJR Am J Roentgenol"},{"key":"9132_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/hep.24422","volume":"54","author":"JN Schouten","year":"2011","unstructured":"Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL (2011) Idiopathic noncirrhotic portal hypertension. Hepatology 54:1071\u20131081","journal-title":"Hepatology"},{"key":"9132_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4254\/wjh.v11.i8.613","volume":"11","author":"S Gioia","year":"2019","unstructured":"Gioia S, Nardelli S, Ridola L, d'Amati G, Riggio O (2019) Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? World J Hepatol 11:613\u2013618","journal-title":"World J Hepatol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-09132-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:22:44Z","timestamp":1675156964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-09132-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["9132"],"URL":"https:\/\/doi.org\/10.1007\/s00330-022-09132-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"1 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Thomas Reiberger.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors have nothing to disclose regarding the work under consideration for publication. The following authors disclose conflicts of interests outside the submitted work: KL, KW, MJ, LH, and LB have nothing to disclose. GS received travel support from Gilead. BSi received travel support from Abbvie and Gilead. DB received travel support from AbbVie and Gilead. MP is an investigator for Bayer, BMS, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, Lilly, and MSD; he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. MT received grant support from Albireo, Almylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and Ultragenyx, and honoraria for consulting from Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, Pliant and Regulus, speaker fees from Bristol-Myers Squibb, Falk, Gilead, Intercept and MSD, as well as travel support from AbbVie, Falk, Gilead, and Intercept. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid. MM served as a speaker and\/or consultant and\/or advisory board member for AbbVie, Collective Acumen, Gilead, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. DT is an investigator for Roche. He received travel support from Siemens and Bayer. JS received grant support from Eli Lilly and Company and Gilead. AB-S received honoraria for lectures and consultancy fees from Bayer. TR received grant support from AbbVie, Boehringer-Ingelheim, Gilead, MSD, Gore, Philips Healthcare, Pliant Pharmaceuticals, Siemens; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche, MSD; consulting\/advisory board fee from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. BS received travel support from AbbVie, Ipsen, and Gilead. MS received travel support from Bayer, speaker honoraria from Takeda, and is an investigator for B\u00f6hringer, Takeda, Allena Pharmaceuticals, and Gilead.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Several authors have significant statistical expertise. Also, no complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"In a prior study, we reported on the clinical characterization of patients with PSVD, being the first of its kind, as well as differences to patients meeting the former definition of INCPH []. This study included 91 patients with PSVD. Also, data on cirrhotic patients included in the prospective VICIS study ( identifier: NCT03541057) have been previously published (e.g., on 234 in the referred study) as this is a prospective registry study with consecutive sampling [].References1. W\u00f6ran K, Semmler G, Jachs M et al (2020) Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension. Clin Gastroenterol Hepatol. 10.1016\/j.cgh.2020.11.0392. Simbrunner B, Semmler G, Stadlmann A et al (2020) Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatol Int 14:1093-1103","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 retrospective\u2022 Case control study\u2022 performed at one institution","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}